Patents by Inventor Paul William Richard Harris
Paul William Richard Harris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200353088Abstract: Disclosed are peptide conjugates that are calcitonin gene-related peptide (CGRP) receptor antagonists comprising a CGRP peptide, wherein at least one amino acid of the peptide is covalently conjugated to a lipid-containing moiety. Also disclosed are pharmaceutical compositions and kits comprising such conjugates, methods of preparing such conjugates, and uses of such antagonists.Type: ApplicationFiled: November 6, 2018Publication date: November 12, 2020Inventors: Paul William Richard Harris, Kerry Martin Loomes, Deborah Lucy Hay, Aqfan Jamaluddin, Christopher Stuart Walker, Elyse Thomasine Williams, Margaret Anne Brimble
-
Publication number: 20170218023Abstract: Embodiments of this invention include synthetic compounds (NRP analogues) of peptides termed neural regeneration peptides (NRPs). NRP analogues are made by substituting amino acids in the native peptide sequence, modifying amino acids chemically, by replacing amino acids with synthetic moieties, by stabilizing ?-turns, acetylation of terminal glycine residues or by cyclization. NRP analogues can be used to treat a variety of conditions involving degeneration of neural cells, and includes treating disorders of the nervous system, including peripheral neuropathy, multiple sclerosis, diabetic peripheral neuropathy, neurotoxin-induced neurodegeneration, and amyotrophic lateral sclerosis.Type: ApplicationFiled: April 13, 2017Publication date: August 3, 2017Inventors: Paul William Richard Harris, Margaret Anne Brimble, Frank Sieg
-
Patent number: 9650418Abstract: Embodiments of this invention include synthetic compounds (NRP analogs) of peptides termed neural regeneration peptides (NRPs). NRP analogs are made by substituting amino acids in the native peptide sequence, modifying amino acids chemically, by replacing amino acids with synthetic moieties, by stabilizing ?-turns, acetylation of terminal glycine residues or by cyclization. NRP analogs can be used to treat a variety of conditions involving degeneration of neural cells, and includes treating disorders of the nervous system, including peripheral neuropathy, multiple sclerosis, diabetic peripheral neuropathy, neurotoxin-induced neurodegeneration, and amyotrophic lateral sclerosis.Type: GrantFiled: May 1, 2015Date of Patent: May 16, 2017Assignee: CURONZ HOLDINGS COMPANY LIMITEDInventors: Paul William Richard Harris, Margaret Anne Brimble, Frank Sieg
-
Publication number: 20150307553Abstract: Embodiments of this invention include synthetic compounds (NRP analogues) of peptides termed neural regeneration peptides (NRPs). NRP analogues are made by substituting amino acids in the native peptide sequence, modifying amino acids chemically, by replacing amino acids with synthetic moieties, by stabilizing ?-turns, acetylation of terminal glycine residues or by cyclization. NRP analogues can be used to treat a variety of conditions involving degeneration of neural cells, and includes treating disorders of the nervous system, including peripheral neuropathy, multiple sclerosis, diabetic peripheral neuropathy, neurotoxin-induced neurodegeneration, and amyotrophic lateral sclerosis.Type: ApplicationFiled: May 1, 2015Publication date: October 29, 2015Inventors: Paul William Richard Harris, Margaret Ann Brimble, Frank Sieg
-
Patent number: 9040485Abstract: Embodiments of this invention include synthetic compounds (NRP analogues) of peptides termed neural regeneration peptides (NRPs). NRP analogues are made by substituting amino acids in the native peptide sequence, modifying amino acids chemically, by replacing amino acids with synthetic moieties, by stabilizaing ?-turns, acetylation of terminal glycine residues or by cyclization. NRP analogues can be used to treat a variety of conditions involving degeneration of neural cells, and includes treating disorders of the nervous system, including peripheral neuropathy, multiple sclerosis, diabetic peripheral neuropathy, neurotoxin-induced neurodegeneration, and amyotrophic lateral sclerosis.Type: GrantFiled: October 15, 2012Date of Patent: May 26, 2015Assignee: CURONZ HOLDINGS COMPANY LIMITEDInventors: Paul William Richard Harris, Margaret Ann Brimble, Frank Sieg
-
Publication number: 20130231289Abstract: Embodiments of this invention include synthetic compounds (NRP analogues) of peptides termed neural regeneration peptides (NRPs). NRP analogues are made by substituting amino acids in the native peptide sequence, modifying amino acids chemically, by replacing amino acids with synthetic moieties, by stabilizaing ?-turns, acetylation of terminal glycine residues or by cyclization. NRP analogues can be used to treat a variety of conditions involving degeneration of neural cells, and includes treating disorders of the nervous system, including peripheral neuropathy, multiple sclerosis, diabetic peripheral neuropathy, neurotoxin-induced neurodegeneration, and amyotrophic lateral sclerosis.Type: ApplicationFiled: October 15, 2012Publication date: September 5, 2013Applicant: Curonz Holdings Company LimitedInventors: Paul William Richard Harris, Margaret Ann Brimble, Frank Sieg
-
Patent number: 8309684Abstract: Embodiments of this invention include synthetic compounds (NRP analogues) of peptides termed neural regeneration peptides (NRPs). NRP analogues are made by substituting amino acids in the native peptide sequence, modifying amino acids chemically, by replacing amino acids with synthetic moieties, by stabilizing ?-turns, acetylation of terminal glycine residues or by cyclization. NRP analogues can be used to treat a variety of conditions involving degeneration of neural cells, and includes treating disorders of the nervous system, including peripheral neuropathy, multiple sclerosis, diabetic peripheral neuropathy, neurotoxin-induced neurodegeneration, and amyotrophic lateral sclerosis.Type: GrantFiled: April 6, 2010Date of Patent: November 13, 2012Assignee: Curonz Holdings Company LimitedInventors: Paul William Richard Harris, Margaret Anne Brimble, Frank Sieg
-
Patent number: 8013170Abstract: Embodiments of this invention provide novel peptidomimetics that contain a macrocycle, an embodiment of which is 2S,9?S,12?S)-2-{[(1?,4?-Diaza-2?-oxobicyclo[7.3.0]dodecyl)-12?-carbonyl]amino}-1,5-pentanedioic acid trifluoroacetate. Such compounds are neuroprotective and have utility as therapeutic agents for treatment of diseases, injuries and other conditions characterized by neuronal degeneration and/or neuronal cell death caused by in embodiments, toxicity or hypoxia. Compounds are also useful for manufacture of medicaments useful for treatment of such conditions.Type: GrantFiled: December 14, 2007Date of Patent: September 6, 2011Inventors: Paul William Richard Harris, Margaret Anne Brimble
-
Publication number: 20110098228Abstract: Embodiments of this invention include synthetic compounds (NRP analogues) of peptides termed neural regeneration peptides (NRPs). NRP analogues are made by substituting amino acids in the native peptide sequence, modifying amino acids chemically, by replacing amino acids with synthetic moieties, by stabilizing ?-turns, acetylation of terminal glycine residues or by cyclization. NRP analogues can be used to treat a variety of conditions involving degeneration of neural cells, and includes treating disorders of the nervous system, including peripheral neuropathy, multiple sclerosis, diabetic peripheral neuropathy, neurotoxin-induced neurodegeneration, and amyotrophic lateral sclerosis.Type: ApplicationFiled: April 6, 2010Publication date: April 28, 2011Applicant: Neuren Pharmaceuticals LimitedInventors: Paul William Richard Harris, Margaret Anne Brimble, Frank Sieg
-
Publication number: 20110052528Abstract: Embodiments of this invention provide novel peptidomimetics that contain a macrocycle. Such compounds are neuroprotective and have utility as therapeutic agents for treatment of diseases, injuries and other conditions characterised by neuronal degeneration and/or death. Compounds are also useful for manufacture of medicaments useful for treatment of such conditions.Type: ApplicationFiled: December 14, 2007Publication date: March 3, 2011Applicant: Neuren Pharmaceuticals LimitedInventors: Paul William Richard Harris, Margaret Anne Brimble
-
Patent number: 7863304Abstract: Embodiments of this invention include novel analogs of Glycyl-Prolyl-Glutamate (GPE) and compositions containing such analogs of GPE. Of these, certain analogs have modified proline residues. Other embodiments of this invention include uses of analogs of GPE to protect neural cells from degeneration and/or death in response to injury or disease. Disorders treatable with compounds and compositions of this invention include hypoxia/ischemia, toxic injury, and chronic neurodegenerative disorders including Parkinson's disease.Type: GrantFiled: November 20, 2007Date of Patent: January 4, 2011Assignee: Neuren Pharmaceuticals LimitedInventors: Margaret Anne Brimble, Paul William Richard Harris, Frank Sieg
-
Patent number: 7485630Abstract: Embodiments of this invention provide novel peptidomimetics that contain a macrocycle. Such compounds are neuroprotective and have utility as therapeutic agents for treatment of diseases, injuries and other conditions characterised by neuronal degeneration and/or death. Compounds are also useful for manufacture of medicaments useful for treatment of such conditions.Type: GrantFiled: March 16, 2004Date of Patent: February 3, 2009Assignee: Neuren Pharmaceuticals LimitedInventors: Paul William Richard Harris, Margaret Anne Brimble
-
Publication number: 20080145335Abstract: Embodiments of this invention include novel analogs of Glycyl-Prolyl-Glutamate (GPE) and compositions containing such analogs of GPE. Of these, certain analogs have modified proline residues. Other embodiments of this invention include uses of analogs of GPE to protect neural cells from degeneration and/or death in response to injury or disease. Disorders treatable with compounds and compositions of this invention include hypoxia/ischemia, toxic injury, and chronic neurodegenerative disorders including Parkinson's disease.Type: ApplicationFiled: November 20, 2007Publication date: June 19, 2008Applicant: Neuren Pharmaceuticals LimitedInventors: Margaret Anne Brimble, Paul William Richard Harris, Frank Sieg